StockMacro
Company, fund or insider

Help

Menu

iRhythm

$94.72 -17% in 6 monthsMarket cap $3.2B

IRTC on XNAS, Health Care, iRhythm Holdings, Inc., job postings

Measures activity, not value. Not investment advice.

Insiders bought $764K in 90 days while shares fell 44% over 12 months.

  • BadShort interest 9.7% of shares, up 5.5% between reports two weeks apart
  • BadLost $38.6M over 12 months on $854M revenue

Written by AI from the data on this page, 21 Nov 2026. Not investment advice.

Profile and fundamentals

From its SEC filings, 12 months to 30 Sep 2026

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.

Industry
Surgical & medical instruments & apparatus (Health Care)
Employees
2,400
Website
irhythmtech.com
Listed
Nasdaq, US
Last results
5 Nov 2026
Next results
expected around 18 Feb 2027 (an estimate: a year ago it reported on 19 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $221.6M, net loss $29.9M.
Quarter to 31 Dec 2021: revenue $81.8M, net income -$32.5MQuarter to 31 Dec 2021: revenue $81.8M, net income -$32.5MQuarter to 31 Mar 2022: revenue $92.4M, net income -$50.6MQuarter to 31 Mar 2022: revenue $92.4M, net income -$50.6MQuarter to 30 Jun 2022: revenue $102.1M, net income -$23.9MQuarter to 30 Jun 2022: revenue $102.1M, net income -$23.9MQuarter to 30 Sep 2022: revenue $103.9M, net income -$21.5MQuarter to 30 Sep 2022: revenue $103.9M, net income -$21.5MQuarter to 31 Dec 2022: revenue $112.6M, net income -$20.2MQuarter to 31 Dec 2022: revenue $112.6M, net income -$20.2MQuarter to 31 Mar 2023: revenue $111.4M, net income -$39.1MQuarter to 31 Mar 2023: revenue $111.4M, net income -$39.1MQuarter to 30 Jun 2023: revenue $124.1M, net income -$18.5MQuarter to 30 Jun 2023: revenue $124.1M, net income -$18.5MQuarter to 30 Sep 2023: revenue $124.6M, net income -$27.1MQuarter to 30 Sep 2023: revenue $124.6M, net income -$27.1MQuarter to 31 Dec 2023: revenue $132.5M, net income -$38.7MQuarter to 31 Dec 2023: revenue $132.5M, net income -$38.7MQuarter to 31 Mar 2024: revenue $131.9M, net income -$45.7MQuarter to 31 Mar 2024: revenue $131.9M, net income -$45.7MQuarter to 30 Jun 2024: revenue $148.0M, net income -$20.1MQuarter to 30 Jun 2024: revenue $148.0M, net income -$20.1MQuarter to 30 Sep 2024: revenue $147.5M, net income -$46.2MQuarter to 30 Sep 2024: revenue $147.5M, net income -$46.2MQuarter to 31 Dec 2024: revenue $164.3M, net income -$1.3MQuarter to 31 Dec 2024: revenue $164.3M, net income -$1.3MQuarter to 31 Mar 2025: revenue $158.7M, net income -$30.7MQuarter to 31 Mar 2025: revenue $158.7M, net income -$30.7MQuarter to 30 Jun 2025: revenue $186.7M, net income -$14.2MQuarter to 30 Jun 2025: revenue $186.7M, net income -$14.2MQuarter to 30 Sep 2025: revenue $192.9M, net income -$5.2MQuarter to 30 Sep 2025: revenue $192.9M, net income -$5.2MQuarter to 31 Dec 2025: revenue $208.9M, net income $5.6MQuarter to 31 Dec 2025: revenue $208.9M, net income $5.6MQuarter to 31 Mar 2026: revenue $199.4M, net income -$13.9MQuarter to 31 Mar 2026: revenue $199.4M, net income -$13.9MQuarter to 30 Jun 2026: revenue $224.2M, net income -$381KQuarter to 30 Jun 2026: revenue $224.2M, net income -$381KQuarter to 30 Sep 2026: revenue $221.6M, net income -$29.9MQuarter to 30 Sep 2026: revenue $221.6M, net income -$29.9M
31 Dec 2021RevenueNet incomeNet losstallest bar $224.2M30 Sep 2026
See the numbers
Quarter toRevenueNet income
30 Sep 2026$221.6M-$29.9M
30 Jun 2026$224.2M-$381K
31 Mar 2026$199.4M-$13.9M
31 Dec 2025$208.9M$5.6M
30 Sep 2025$192.9M-$5.2M
30 Jun 2025$186.7M-$14.2M
31 Mar 2025$158.7M-$30.7M
31 Dec 2024$164.3M-$1.3M
30 Sep 2024$147.5M-$46.2M
30 Jun 2024$148.0M-$20.1M
31 Mar 2024$131.9M-$45.7M
31 Dec 2023$132.5M-$38.7M
30 Sep 2023$124.6M-$27.1M
30 Jun 2023$124.1M-$18.5M
31 Mar 2023$111.4M-$39.1M
31 Dec 2022$112.6M-$20.2M
30 Sep 2022$103.9M-$21.5M
30 Jun 2022$102.1M-$23.9M
31 Mar 2022$92.4M-$50.6M
31 Dec 2021$81.8M-$32.5M
Fundamentals, 12 months to 30 Sep 2026
MeasureLatestYear beforePeer median
RevenueSales over the last 12 months reported. $854.0M $702.6M
Revenue growthRevenue of the last 12 months compared with the 12 months before. +22% +13%
Net incomeProfit after all costs and taxes over the last 12 months reported. Negative is a loss. -$38.6M -$51.5M
EPS (diluted)Earnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split). -$1.16 -$1.61
Gross marginWhat is left of each dollar of sales after the direct cost of making the product or service. 72.3% 70.4% 60.5%
Operating marginOperating income as a share of sales: profit from the business before interest and taxes. -5.7% -9.1% -8.3%
Net marginNet income as a share of sales: what the owners keep of each dollar sold. -4.5% -7.3% -10.1%
Return on equityNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money. -25.8% -26.3%
Free cash flowCash from operations minus capital spending over the last 12 months: cash the business produced. $7.4M $32.4M
CashCash, cash equivalents and short-term investments on the latest balance sheet. $560.7M $565.2M
DebtShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted. $651.9M $648.8M
Net debtDebt minus cash. Negative means the company holds more cash than it owes (net cash). $91.1M $83.5M
Debt to equityDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative. 3.7 0.31
Book value per shareShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding. $5.27
P/EPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss. loss 28.0
P/SPrice to sales: market cap divided by revenue of the last 12 months. 3.7 2.3
EV/SalesEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months. 3.8 2.5
P/BPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative. 18.0 2.8

Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.

Peers nearest by market cap, its own industry first

CompanyMarket capP/EP/SRevenue growthNet margin
iRhythmIRTC (this company) $3.2Bloss3.7+22%-4.5%
Pulse BiosciencesPLSE $3.4Blossover 999+1637%–
AtriCureATRC $2.8B1904.8+14%2.5%
HeartflowHTFL $4.1Bloss17.2+47%-33.1%
ICU MedicalICUI $4.3B71.52.0-5.9%2.8%
UFP TechnologiesUFPT $2.3B29.43.5+8.6%11.8%

Revenue growth Sales in the latest reported quarter compared with the same quarter a year earlier.

+15%

$221.6M vs $192.9M (quarter ended 30 Sep 2026)

Capital spending Money spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.

+7.8%

$16.0M vs $14.8M (quarter ended 30 Sep 2026)

Insider buy/sell Shares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.

+$670K

bought $764K, sold $94K

Institutional holders The number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.

+5.3%

316 13F filers vs 300

Institutional ownership Shares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.

over 100%

36.1M shares held by 13F filers (30 Sep 2026) of 33.6M outstanding (29 Oct 2026); above 100%: the share count is probably stale

Short interest Shares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.

9.7%

3.3M shares sold short (30 Oct 2026) of 33.6M outstanding (29 Oct 2026)

Days to cover Short interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.

6.7

3.3M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it

Short interest change How the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.

+5.5%

3.1M shares sold short in the report before, 3.3M on 30 Oct 2026

Short sale volume Share of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.

49%

49% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%

Lobbying What the company reported spending on federal lobbying over the last four quarters.

$200K

4 quarters

News Articles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.

27

27 articles in the last 7 days; its usual week has 3 (the median of the 26 weeks before).

News vs usual Articles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.

9.0×

27 articles in the last 7 days; its usual week has 3.

Unusual now sharp changes in the last 90 days, compared with its own past

  • New lobbying issue

Price $94.72 on 20 Nov 2026, -44% over 12 months (12-month range $86.06 to $189.25)

  • Sharp change
  • 8-K and other filings
  • Lobbying filing
Insider net buying (open market). Insiders sold a net $23.7M in the last 12 months (the 12 months before: -$25.7M).
H-1B/E-3 applications certified. H-1B/E-3 applications certified: 3 published in the last 12 months (none in the 12 months before).
Revenue per quarter. Revenue $221.6M in the latest quarter, +15% on a year earlier.
Capital spending per quarter. Capital spending $16.0M in the latest quarter, +7.8% on a year earlier.
Institutional holders (13F filers). 316 13F filers reported holding it in the latest 13F quarter, +0.6% on a year earlier.
Lobbying spend. Lobbying spend: $200K published in the last 12 months, -17% on the 12 months before.

Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.

See the numbers
Dated facts on the price chart (newest 100)
Became publicKindFact
13 Nov 20268-K and other filingsAdopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees
13 Nov 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Oct 2026Sharp changeLobbying on a new issue: lobbying on a new issue: VET (2026-09-30)
13 Aug 20268-K and other filingsDirector or officer change
15 Jun 20268-K and other filingsMaterial cybersecurity incident
28 May 20268-K and other filingsDirector or officer change
8 May 2026Lobbying filingnew lobbying registration (MEHLMAN CONSULTING, INC.)
16 Apr 2026Lobbying filinglobbying engagement terminated (DLA PIPER LLP (US))
31 Mar 20268-K and other filingsChanged its auditor
12 Mar 20268-K and other filingsDirector or officer change
12 Mar 2026Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
4 Nov 2025Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 14.8M vs usual 9.3M (2025-09-30); 1.7x the same period a year earlier
30 Oct 20258-K and other filingsDirector or officer change
30 Oct 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Aug 2025Sharp changeMany funds opening a new position: many funds opening a new position, 64 vs usual 28.50 (2025-06-30); 2.8x the same period a year earlier
7 Jul 20258-K and other filingsDirector or officer change
7 Jul 2025Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
15 May 2025Sharp changeMany funds opening a new position: many funds opening a new position, 49 vs usual 26.50 (2025-03-31); 1.0x the same period a year earlier
27 Jan 20258-K and other filingsDirector or officer change
19 Nov 2024Sharp changeMany funds opening a new position: many funds opening a new position, 40 vs usual 25.50 (2024-09-30); 1.3x the same period a year earlier
13 Nov 20248-K and other filingsDirector or officer change
13 Nov 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
11 Oct 2024Lobbying filinglobbying engagement terminated (WILLIAMS AND JENSEN, PLLC)
4 Oct 2024Lobbying filingnew lobbying registration (DLA PIPER LLP (US))
1 Aug 20248-K and other filingsDirector or officer change
1 Aug 2024Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
21 May 2024Sharp changeMany funds opening a new position: many funds opening a new position, 49 vs usual 26.50 (2024-03-31); 1.8x the same period a year earlier
8 Jan 20248-K and other filingsA major agreement ended
15 Aug 20238-K and other filingsDirector or officer change
10 Aug 20238-K and other filingsDirector or officer change
6 Jun 20238-K and other filingsDirector or officer change
15 Mar 20238-K and other filingsDirector or officer change
15 Mar 2023Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
9 Aug 2022Sharp changeQuarterly capital spending jump: quarterly capital spending jump, 10.8M vs usual 5.1M (2022-06-30); 1.8x the same period a year earlier
25 Jul 20228-K and other filingsDirector or officer change
18 Jul 20228-K and other filingsDirector or officer change
18 Jul 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
14 Mar 20228-K and other filingsDirector or officer change
14 Mar 2022Sharp changeDirector or officer change (8-K item 5.02): director or officer change (8-K item 5.02) (1 event(s) in 90 days)
20 Jan 2022Sharp changeLobbying on a new issue: lobbying on a new issue: MMM (2021-12-31)
1 Dec 20218-K and other filingsDirector or officer change
Insider net buying (open market)
Month from 1 Feb 2022: -$1.7M published
Month from 1 Mar 2022: -$2.1M published
Month from 1 Jun 2022: -$56K published
Month from 1 Jul 2022: -$1.4M published
Month from 1 Sep 2022: -$382K published
Month from 1 Oct 2022: -$250K published
Month from 1 Nov 2022: -$1.6M published
Month from 1 Dec 2022: -$291K published
Month from 1 Mar 2023: -$2.0M published
Month from 1 Jun 2023: -$124K published
Month from 1 Jul 2023: -$256K published
Month from 1 Aug 2023: -$341K published
Month from 1 Dec 2023: -$150K published
Month from 1 Jan 2024: -$746K published
Month from 1 Mar 2024: -$6.0M published
Month from 1 Jun 2024: -$146K published
Month from 1 Jul 2024: -$148K published
Month from 1 Aug 2024: -$352K published
Month from 1 Nov 2024: -$749K published
Month from 1 Dec 2024: -$214K published
Month from 1 Feb 2025: -$7.8M published
Month from 1 Mar 2025: -$2.3M published
Month from 1 May 2025: -$1.3M published
Month from 1 Jun 2025: -$968K published
Month from 1 Jul 2025: -$206K published
Month from 1 Aug 2025: -$6.8M published
Month from 1 Sep 2025: -$998K published
Month from 1 Nov 2025: -$5.2M published
Month from 1 Dec 2025: -$510K published
Month from 1 Feb 2026: -$10.4M published
Month from 1 Mar 2026: -$4.8M published
Month from 1 May 2026: -$692K published
Month from 1 Jun 2026: -$265K published
Month from 1 Jul 2026: -$292K published
Month from 1 Aug 2026: -$7.3M published
Month from 1 Sep 2026: -$94K published
Month from 1 Nov 2026: $764K published
H-1B/E-3 applications certified
Quarter from 1 Oct 2026: 3 published
Revenue per quarter
Quarter ended 31 Dec 2021: $81.8M, +3.8% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $92.4M, +24% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $102.1M, +26% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $103.9M, +22% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $112.6M, +38% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $111.4M, +21% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $124.1M, +22% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $124.6M, +20% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $132.5M, +18% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $131.9M, +18% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $148.0M, +19% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $147.5M, +18% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $164.3M, +24% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $158.7M, +20% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $186.7M, +26% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $192.9M, +31% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $208.9M, +27% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $199.4M, +26% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $224.2M, +20% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $221.6M, +15% on a year earlier; public on 6 Nov 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $4.6M, +96% on a year earlier; public on 1 Mar 2022
Quarter ended 31 Mar 2022: $5.6M, +32% on a year earlier; public on 7 May 2022
Quarter ended 30 Jun 2022: $10.8M, +83% on a year earlier; public on 6 Aug 2022
Quarter ended 30 Sep 2022: $6.3M, -52% on a year earlier; public on 5 Nov 2022
Quarter ended 31 Dec 2022: $7.1M, +53% on a year earlier; public on 24 Feb 2023
Quarter ended 31 Mar 2023: $8.4M, +51% on a year earlier; public on 5 May 2023
Quarter ended 30 Jun 2023: $9.4M, -13% on a year earlier; public on 5 Aug 2023
Quarter ended 30 Sep 2023: $9.1M, +43% on a year earlier; public on 3 Nov 2023
Quarter ended 31 Dec 2023: $13.5M, +91% on a year earlier; public on 23 Feb 2024
Quarter ended 31 Mar 2024: $9.8M, +16% on a year earlier; public on 3 May 2024
Quarter ended 30 Jun 2024: $8.5M, -9.7% on a year earlier; public on 2 Aug 2024
Quarter ended 30 Sep 2024: $8.8M, -2.8% on a year earlier; public on 31 Oct 2024
Quarter ended 31 Dec 2024: $6.8M, -49% on a year earlier; public on 21 Feb 2025
Quarter ended 31 Mar 2025: $9.4M, -3.7% on a year earlier; public on 2 May 2025
Quarter ended 30 Jun 2025: $10.4M, +22% on a year earlier; public on 1 Aug 2025
Quarter ended 30 Sep 2025: $14.8M, +68% on a year earlier; public on 31 Oct 2025
Quarter ended 31 Dec 2025: $11.7M, +71% on a year earlier; public on 20 Feb 2026
Quarter ended 31 Mar 2026: $6.9M, -27% on a year earlier; public on 1 May 2026
Quarter ended 30 Jun 2026: $13.6M, +31% on a year earlier; public on 7 Aug 2026
Quarter ended 30 Sep 2026: $16.0M, +7.8% on a year earlier; public on 6 Nov 2026
Institutional holders (13F filers)
31 Dec 2021 report: 197; public on 14 Feb 2022
31 Mar 2022 report: 210; public on 16 May 2022
30 Jun 2022 report: 227; public on 15 Aug 2022
30 Sep 2022 report: 208; public on 14 Nov 2022
31 Dec 2022 report: 190; public on 14 Feb 2023
31 Mar 2023 report: 193; public on 15 May 2023
30 Jun 2023 report: 188; public on 14 Aug 2023
30 Sep 2023 report: 207; public on 14 Nov 2023
31 Dec 2023 report: 213; public on 14 Feb 2024
31 Mar 2024 report: 243; public on 15 May 2024
30 Jun 2024 report: 214; public on 14 Aug 2024
30 Sep 2024 report: 232; public on 14 Nov 2024
31 Dec 2024 report: 220; public on 14 Feb 2025
31 Mar 2025 report: 243; public on 15 May 2025
30 Jun 2025 report: 291; public on 14 Aug 2025
30 Sep 2025 report: 314; public on 14 Nov 2025
31 Dec 2025 report: 322; public on 17 Feb 2026
31 Mar 2026 report: 295; public on 15 May 2026
30 Jun 2026 report: 300; public on 14 Aug 2026
30 Sep 2026 report: 316; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Jan 2022: $30K published
Quarter from 1 Apr 2022: $60K published
Quarter from 1 Jul 2022: $60K published
Quarter from 1 Oct 2022: $60K published
Quarter from 1 Jan 2023: $60K published
Quarter from 1 Apr 2023: $60K published
Quarter from 1 Jul 2023: $60K published
Quarter from 1 Oct 2023: $60K published
Quarter from 1 Jan 2024: $60K published
Quarter from 1 Apr 2024: $60K published
Quarter from 1 Jul 2024: $60K published
Quarter from 1 Oct 2024: $50K published
Quarter from 1 Jan 2025: $60K published
Quarter from 1 Apr 2025: $60K published
Quarter from 1 Jul 2025: $60K published
Quarter from 1 Oct 2025: $60K published
Quarter from 1 Jan 2026: $60K published
Quarter from 1 Apr 2026: $40K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $50K published

What is unusual now

Latest records

The names and amounts behind the totals, newest first

Last 90 days: 1 sale, $94K; 1 purchase, $764K. Open-market trades by officers, directors and 10% owners.

FiledInsiderTradeSharesPriceValueSource
19 Nov 2026Abhijit Y TalwalkarDirectorBuy7,900$96.67$764KForm 4
3 Sep 2026Daniel G. WilsonChief Financial OfficerSell773$121.83$94KForm 4
11 Aug 2026Patrick Michael MurphyCBO and CLOSell7,093$124.65$884KForm 4
11 Aug 2026Quentin S. BlackfordPresident and CEOSell26,859$124.65$3.3MForm 4
11 Aug 2026Sumi ShrishrimalEVP, Chief Risk OfficerSell5,372$124.65$670KForm 4
11 Aug 2026Minang TurakhiaCHIEF MED/SCI OFCR EVP ADVTECHSell7,093$124.65$884KForm 4
11 Aug 2026Chad PattersonCHIEF COMM & PRODUCT OFFICERSell7,093$124.65$884KForm 4
4 Aug 2026Mervin SmithEVP Strategic Business OpsSell617$122.12$75KForm 4

316 institutions reported shares at the end of Q3 2026, 100% of the shares outstanding; 51 opened a position, 39 sold out. From 13F reports.

InstitutionShares% of companyValueChange vs Q2 2026
RTW Investments, LP3.1M9.28%$354.5M+936K+43%
BlackRock, Inc.3.0M8.94%$341.7M+21K+0.7%
Artisan Partners Limited Partnership2.2M6.53%$249.6M+536K+32%
Vanguard Portfolio Management LLC2.0M5.89%$225.2M+67K+3.5%
Vanguard Capital Management LLC1.5M4.36%$166.5M+1,835+0.1%
BNP PARIBAS ASSET MANAGEMENT Holding S.A.1.1M3.32%$127.0M+251K+29%
Eventide Asset Management, LLC909K2.70%$103.3M+29K+3.3%
State Street Corp864K2.57%$98.2M+7,170+0.8%
Geode Capital Management, LLC861K2.56%$97.8M-21K-2.4%
FMR LLC (Fidelity)834K2.48%$94.8M-358K-30%

Company events

All 65 company events

In 12 months: 4 director or officer changes, 2 major agreements, 1 auditor change, 1 cybersecurity incident. Results releases and routine reports are left out.

FiledWhat happenedSource
13 Nov 2026Adopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees8-K
13 Aug 2026Director or officer change8-K
6 Aug 2026Signed a major agreement8-K
6 Aug 2026Signed a major agreementSame filing: sold shares privately8-K
15 Jun 2026Material cybersecurity incident8-K
28 May 2026Director or officer changeSame filing: shareholder vote results8-K
31 Mar 2026Changed its auditor8-K
12 Mar 2026Director or officer change8-K

Reported lobbying spend: $50K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.

DateChangeLobbying firmIssueSource
1 Apr 2026NewMehlman Consulting, Inc.for Irhythm Technologies, Inc.Ensuring access to appropriate medical technology for cardiac patients.Health issues, Medicare/Medicaid, VETFiling
25 Feb 2026EndedDla Piper LLP (US)for Irhythm Technologies, Inc.Issues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to Medicare physician fee schedule.Medicare/MedicaidFiling
1 Aug 2024NewDla Piper LLP (US)for Irhythm Technologies, Inc.Issues related to CMS payment policy, telehealth.Medicare/MedicaidFiling
19 Jul 2024EndedWilliams And Jensen, PLLCfor Irhythm TechnologiesIssues related to CMS payment policy and telehealth. Issues related to Medicare technology paid pursuant to the Medicare Physician Fee Schedule. Issues related to Covid 19.; Issues related to artificial intelligence.Medicare/Medicaid, Health issuesFiling
1 Nov 2021NewWilliams And Jensen, PLLCfor Irhythm TechnologiesIssues related to CMS payment policy, telehealth.Medicare/MedicaidFiling
1 May 2013EndedThe Korris Group, Inc.for Irhythm Technologies, Inc.Not statedFiling
1 Jan 2011NewThe Korris Group, Inc.for Irhythm Technologies, Inc.Medicare coverage and payment for cardiac rhythm/event monitoringHealth issuesFiling

The 5 newest of 237 articles that name the company.

Timeline

Several things at once

Two or more unrelated kinds of records unusual within 30 days

17 Nov 2021confirmed

Confirmed across sources Filings + Financials and Lobbying

iRhythm (IRTC): spent $13.3M on capital projects in the quarter ended 30 Sep 2021, 2.4× the same quarter last year, while it registered for federal lobbying for the first time in our data (Williams And Jensen, Pllc). Two unrelated kinds of activity within 7 days.

  • Financials: Quarterly capital spending jump, became public on 9 Nov 2021
  • Lobbying: First lobbying registration, became public on 17 Nov 2021
2019-06-30: $2.8M2019-09-30: $3.4M2019-12-31: $11.8M2020-03-31: $3.4M2020-09-30: $5.6M2020-12-31: $2.4M2021-03-31: $4.2M2021-06-30: $5.9M2021-09-30: $13.3M
The quarter ended 30 Sep 2021 against the 8 quarters before it. this quarterearliernormal: $3.8M
See the evidence (2 changes)

Financials: Quarterly capital spending jump became public on 9 Nov 2021

iRhythm spent $13.3M on capital projects in the quarter ended 30 Sep 2021, 2.4× the same quarter last year.

This period
$13.3M (the quarter ended 30 Sep 2021)
Normal quarter (median of 8 earlier)
$3.8M
Typical spread (median absolute deviation)
$1.2M
How far from its usual level
+5.3
Same quarter last year
$5.6M
History used
2,100 days
2019-06-30: $2.8M2019-09-30: $3.4M2019-12-31: $11.8M2020-03-31: $3.4M2020-09-30: $5.6M2020-12-31: $2.4M2021-03-31: $4.2M2021-06-30: $5.9M2021-09-30: $13.3M
the quarter ended 30 Sep 20218 earlier quartersnormal: $3.8M

Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

Check it at the source: SEC EDGAR quarterly reports.

Lobbying: First lobbying registration became public on 17 Nov 2021

iRhythm registered for federal lobbying for the first time in our data (Williams And Jensen, Pllc).

Source coverage starts
4 Jan 2010
Earlier events of other kinds
0

"First" means first in our data: it fires only when the source's history began at least 365 days earlier.

Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.

Timeline

Changes and notable records, by the date each became public

  1. 19 Nov 2026Insiders record

    TALWALKAR ABHIJIT Y (director) bought 7,900 shares of IRTC ($763,706)

  2. 13 Nov 2026Filings change

    filed a director or officer change: Adopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  3. 13 Nov 2026Filings record

    Adopted a nonqualified deferred compensation plan effective Jan 1, 2027, letting employees and directors defer salary, bonus and fees

  4. 20 Oct 2026Lobbying change

    lobbying on a new issue.

    See the evidence
    New
    ['VET']
    Rule
    only points whose every posting (and value revision) is at or before as_of
    Field
    issue_codes
    Metric
    lobbying.filings_count
    Point id
    4289524
  5. 13 Aug 2026Filings record

    Director or officer change

  6. 15 Jun 2026Filings record

    Material cybersecurity incident

  7. 28 May 2026Filings record

    Director or officer change

  8. 13 May 2026Insiders record

    TALWALKAR ABHIJIT Y (director) bought 5,312 shares of IRTC ($56,892) (dated 12 May 2026)

  9. 8 May 2026Lobbying record

    IRHYTHM TECHNOLOGIES, INC.: new lobbying registration (MEHLMAN CONSULTING, INC.) (dated 1 Apr 2026)

  10. 16 Apr 2026Lobbying record

    IRHYTHM TECHNOLOGIES, INC.: lobbying engagement terminated (DLA PIPER LLP (US)) (dated 25 Feb 2026)

  11. 31 Mar 2026Filings record

    Changed its auditor

  12. 12 Mar 2026Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  13. 12 Mar 2026Filings record

    Director or officer change

  14. 4 Nov 2025Financials change

    spent $14.8M on capital projects in the quarter ended 30 Sep 2025, 1.7× the same quarter last year.

    Same quarter last year: $8.8M; its normal quarter is $9.3M.

    See the evidence
    This period
    $14.8M (the quarter ended 30 Sep 2025)
    Normal quarter (median of 8 earlier)
    $9.3M
    Typical spread (median absolute deviation)
    $644K
    How far from its usual level
    +5.6
    Same quarter last year
    $8.8M
    History used
    3,561 days
    2023-09-30: $9.1M2023-12-31: $13.5M2024-03-31: $9.8M2024-06-30: $8.5M2024-09-30: $8.8M2024-12-31: $6.8M2025-03-31: $9.4M2025-06-30: $10.4M2025-09-30: $14.8M
    the quarter ended 30 Sep 20258 earlier quartersnormal: $9.3M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  15. 30 Oct 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  16. 30 Oct 2025Filings record

    Director or officer change

  17. 14 Aug 2025Institutional holdings change

    saw 64 13F filers open a new position in the quarter ended 30 Jun 2025, 2.8× the same quarter last year.

    Same quarter last year: 23; its normal quarter is 28.5.

    See the evidence
    This period
    64 (the quarter ended 30 Jun 2025)
    Normal quarter (median of 8 earlier)
    28.5
    Typical spread (median absolute deviation)
    4.5
    How far from its usual level
    +5.3
    Same quarter last year
    23
    History used
    3,103 days
    2023-06-30: 252023-09-30: 312023-12-31: 262024-03-31: 492024-06-30: 232024-09-30: 402024-12-31: 252025-03-31: 492025-06-30: 64
    the quarter ended 30 Jun 20258 earlier quartersnormal: 28.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  18. 7 Jul 2025Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  19. 7 Jul 2025Filings record

    Director or officer change

  20. 15 May 2025Institutional holdings change

    saw 49 13F filers open a new position in the quarter ended 31 Mar 2025, 1.0× the same quarter last year.

    Same quarter last year: 49; its normal quarter is 26.5.

    See the evidence
    This period
    49 (the quarter ended 31 Mar 2025)
    Normal quarter (median of 8 earlier)
    26.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +6.1
    Same quarter last year
    49
    History used
    3,012 days
    2023-03-31: 272023-06-30: 252023-09-30: 312023-12-31: 262024-03-31: 492024-06-30: 232024-09-30: 402024-12-31: 252025-03-31: 49
    the quarter ended 31 Mar 20258 earlier quartersnormal: 26.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  21. 27 Jan 2025Filings record

    Director or officer change

  22. 14 Nov 2024Institutional holdings change

    saw 40 13F filers open a new position in the quarter ended 30 Sep 2024, 1.3× the same quarter last year.

    Same quarter last year: 31; its normal quarter is 25.5.

    See the evidence
    This period
    40 (the quarter ended 30 Sep 2024)
    Normal quarter (median of 8 earlier)
    25.5
    Typical spread (median absolute deviation)
    2
    How far from its usual level
    +4.8
    Same quarter last year
    31
    History used
    2,830 days
    2022-09-30: 252022-12-31: 232023-03-31: 272023-06-30: 252023-09-30: 312023-12-31: 262024-03-31: 492024-06-30: 232024-09-30: 40
    the quarter ended 30 Sep 20248 earlier quartersnormal: 25.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  23. 13 Nov 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  24. 13 Nov 2024Filings record

    Director or officer change

  25. 6 Nov 2024Insiders record

    TALWALKAR ABHIJIT Y (director) bought 6,664 shares of IRTC ($500,866) (dated 5 Nov 2024)

  26. 11 Oct 2024Lobbying record

    IRHYTHM TECHNOLOGIES: lobbying engagement terminated (WILLIAMS AND JENSEN, PLLC) (dated 19 Jul 2024)

  27. 4 Oct 2024Lobbying record

    IRHYTHM TECHNOLOGIES, INC.: new lobbying registration (DLA PIPER LLP (US)) (dated 1 Aug 2024)

  28. 6 Aug 2024Insiders record

    Patterson Chad (Chief Commercial Officer) bought 280 shares of IRTC ($20,994) (dated 5 Aug 2024)

  29. 1 Aug 2024Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  30. 1 Aug 2024Filings record

    Director or officer change

  31. 15 May 2024Institutional holdings change

    saw 49 13F filers open a new position in the quarter ended 31 Mar 2024, 1.8× the same quarter last year.

    Same quarter last year: 27; its normal quarter is 26.5.

    See the evidence
    This period
    49 (the quarter ended 31 Mar 2024)
    Normal quarter (median of 8 earlier)
    26.5
    Typical spread (median absolute deviation)
    2.5
    How far from its usual level
    +6.1
    Same quarter last year
    27
    History used
    2,647 days
    2022-03-31: 322022-06-30: 412022-09-30: 252022-12-31: 232023-03-31: 272023-06-30: 252023-09-30: 312023-12-31: 262024-03-31: 49
    the quarter ended 31 Mar 20248 earlier quartersnormal: 26.5

    Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.

    Check it at the source: SEC Form 13F data sets.

  32. 8 Jan 2024Filings record

    A major agreement ended

  33. 7 Dec 2023Insiders record

    Blackford Quentin S. (President and CEO) bought 9,755 shares of IRTC ($997,644) [amended] (dated 6 Dec 2023)

  34. 15 Aug 2023Filings record

    Director or officer change

  35. 10 Aug 2023Filings record

    Director or officer change

  36. 6 Jun 2023Filings record

    Director or officer change

  37. 15 Mar 2023Filings change

    filed a director or officer change (8-K item 5.02), its first in 90 days.

    Item 5.02 covers departures and appointments alike, so this never counts toward a “several things at once”.

    See the evidence (1 source record)
    Filings in the window
    1

    Fires on an 8-K with item 5.02 after 90 days without one.

  38. 15 Mar 2023Filings record

    Director or officer change

  39. 9 Aug 2022Financials change

    spent $10.8M on capital projects in the quarter ended 30 Jun 2022, 1.8× the same quarter last year.

    Same quarter last year: $5.9M; its normal quarter is $5.1M.

    See the evidence
    This period
    $10.8M (the quarter ended 30 Jun 2022)
    Normal quarter (median of 8 earlier)
    $5.1M
    Typical spread (median absolute deviation)
    $856K
    How far from its usual level
    +4.5
    Same quarter last year
    $5.9M
    History used
    2,373 days
    2020-03-31: $3.4M2020-09-30: $5.6M2020-12-31: $2.4M2021-03-31: $4.2M2021-06-30: $5.9M2021-09-30: $13.3M2021-12-31: $4.6M2022-03-31: $5.6M2022-06-30: $10.8M
    the quarter ended 30 Jun 20228 earlier quartersnormal: $5.1M

    Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.

    Check it at the source: SEC EDGAR quarterly reports.

  40. 25 Jul 2022Filings record

    Director or officer change

Showing the newest 40 of 104 entries; narrow the window or the kind of data to see older ones.

Not listed: 333 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.

Identifiers and sources

How records are matched to this company, and what each source holds for it

Cik
0001388658
Ticker
IRTC
Domain
irhythmtech.com
Employer name
irhythm technologies (1 unverified)
Hq location
CA|SAN FRANCISCO|94103 (1 unverified)
Lobbying client
irhythm technologies
Name
EX-21.1, ex211listofsubsidiaries, ex211listofsubsidiaries.htm, iRhythm Holdings, Inc. and 1 more
  • DOL H-1B labor condition applications and PERM certifications19 data points9 Mar 2026 to 14 Sep 2026
  • Federal lobbying disclosures (LDA)7 records, 84 data points1 Jan 2011 to 30 Sep 2026
  • SEC Form 13F institutional holdings1 record, 360 data points31 Dec 2016 to 30 Sep 2026
  • SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)162 records23 Sep 2016 to 17 Nov 2026
  • SEC XBRL company facts (revenue, capex, R&D, backlog...)925 data points31 Dec 2013 to 29 Oct 2026
  • SEC Form 4 insider transactions232 records, 592 data points25 Oct 2016 to 19 Nov 2026
  • FINRA short interest (twice monthly)624 data points29 Dec 2017 to 30 Oct 2026
  • FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026